A recent large study was reported in the Brown University Geriatric Psychopharmacology Update (November 2010). Improvement was noted for Lewy body as opposed to Parksonian dementia when the study was completed at 24 weeks in terms of behavior but not thinking ability. At 12 weeks there was improvement seen in patients with Parksonian dementia but not the Lewy body group showed significant improvement on this medication. However at 24 weeks only those treated who had Lewy body dementia revealed significant improvement. Scores improved with regard to symptoms of delusions, hallucinations, sleep or nighttime behavior and appetite or eating disorder. No different seen on scores testing cognition or activities of daily living. This does suggest the benefit of this medication for dementia for behavioral issues, again illustrating that typically with this medication there are no changes outwardly with cognition, hence the need for brain or cognitive training. The hypothesis being that the medication acts to prevent further decline but cannot restore what was lost.